02:40 PM EDT, 05/29/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target to $120 from $126, 19.7x our FY 26 EPS estimate. This is a discount to A's five-year forward P/E average of 26.8x but justified by the company's moderate growth outlook in a challenging operating environment. We keep our FY 25 EPS at $5.59 and lower FY 26's to $6.10 from $6.18. Agilent ( A ) reported better-than-expected Apr-Q results amid the complex business environment it is navigating. Q2 FY 25 sales of $1.67B, up 6.0% Y/Y, were slightly better than anticipated, with M&A contributing 2.3% above expectations. Growth was broad-based with the exception of U.S. Academia and Government. Although 8% of Agilent's ( A ) revenue was tied to NIH funding in Apr-Q, we think uncertainties about U.S. federal funding and the global trade environment could weigh on sentiment. Agilent ( A ) penciled in a $50M gross incremental tariff exposure for FY 25 in addition to the $10M accounted for in 1H FY 25. Yet, if tariffs on EU products are enacted in July, we anticipate a larger impact in 2H FY 25.